FDA Approves AbbVie's Skyrizi for Pediatric Psoriasis Patients
AbbVie (ABBV) announced FDA approval of Skyrizi (risankizumab-rzaa) for pediatric patients aged 6 years and older with moderate-to-severe plaque psoriasis. This label expansion strengthens AbbVie's dermatology pipeline and comes ahead of its July 15 ex-dividend date.
AbbVie Inc. (NYSE:ABBV) announced that the U.S. Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients aged 6 years and older. The approval is based on clinical trials demonstrating efficacy and safety in this age group.
The Product
Skyrizi is a biologic that targets interleukin-23 (IL-23), a key protein involved in psoriasis inflammation. Previously approved for adults, this pediatric indication expands its patient population.
Pricing and Availability
AbbVie has not disclosed specific pricing for pediatric doses. The drug is expected to be available by prescription in the coming weeks.
Competition
Skyrizi competes with other biologics such as Stelara (Janssen), Cosentyx (Novartis), and Taltz (Eli Lilly), which are also approved for pediatric psoriasis. Skyrizi's unique mechanism may offer a competitive edge.
Potential Impact on the Company
The expanded approval is expected to boost AbbVie's revenue, particularly as Humira faces biosimilar competition. ABBV stock offers a attractive dividend yield, with the next ex-dividend date on July 15.
Frequently Asked Questions
Found this useful? Share it